[1]刘莉,李娜,邹国良,等.胰岛素抵抗和心房颤动[J].国际心血管病杂志,2022,04:203-205.
点击复制
胰岛素抵抗和心房颤动(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年04期
- 页码:
- 203-205
- 栏目:
- 综述
- 出版日期:
- 2022-08-30
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.04.004
- 文献标识码:
- -
- 摘要:
- 危险因素的控制是预防新发心房颤动（房颤）及不良心血管事件的关键。胰岛 素稳态在房颤发病风险中发挥重要作用，提高胰岛素敏感性可能对房颤预后有积极作用。该 文从胰岛素抵抗与房颤发病风险、预后及病理生理机制（如心房重构、炎性反应与氧化应激、 肾素- 血管紧张素- 醛固酮系统激活等）方面，探讨二者关系。
- Abstract:
- -
参考文献/References
[1] Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of
the Asia Pacific Heart Rhythm Society on stroke prevention in
atrial fibrillation[J]. J Arrhythm, 2017, 33(4):345-367.
[2] Ahn HJ, Han KD, Choi EK, et al. Cumulative burden of
metabolic syndrome and its components on the risk of
atrial fibrillation: a nationwide population-based study[J].
Cardiovasc Diabetol, 2021, 20(1):20.
[3] Decker JJ, Norby FL, Rooney MR, et al. Metabolic syndrome
and risk of ischemic stroke in atrial fibrillation: ARIC study[J].
Stroke, 2019, 50(11):3045-3050.
[4] Latini R, Staszewsky L, Sun JL, et al. Incidence of atrial
fibrillation in a population with impaired glucose tolerance: the
contribution of glucose metabolism and other risk factors. A
post hoc analysis of the Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research trial[J]. Am Heart J,
2013, 166(5):935-940.
[5] Lee Y, Cha SJ, Park JH, et al. Association between insulin
resistance and risk of atrial fibrillation in non-diabetics[J]. Eur
J Prev Cardiol, 2020, 27(18):1934-1941.
[6] Karam BS, Chavez-Moreno A, Koh W, et al. Oxidative stress
and inflammation as central mediators of atrial fibrillation in
obesity and diabetes[J]. Cardiovasc Diabetol, 2017, 16(1):120.
[7] Fontes JD, Lyass A, Massaro JM, et al. Insulin resistance and
atrial fibrillation (from the Framingham Heart Study)[J]. Am J
Cardiol, 2012, 109(1):87-90.
[8] Hijioka N, Kamioka M, Matsumoto Y, et al. Clinical impact
of insulin resistance on pulmonary vein isolation outcome in
patients with paroxysmal atrial fibrillation[J]. J Cardiovasc
Electrophysiol, 2019, 30(4):479-486.
[9] Rundek T, Gardener H, Xu Q, et al. Insulin resistance and risk of
ischemic stroke among nondiabetic individuals from the northern
Manhattan study[J]. Arch Neurol, 2010, 67(10):1195-1200.
[10] Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes:
Prevalence, etiology, pathophysiology and effect of anti-diabetic
therapies[J]. Diabetes Obes Metab, 2019, 21(2):210-217.
[11] Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone
attenuates inflammatory atrial fibrosis and vulnerability to
atrial fibrillation induced by pressure overload in rats[J]. Heart
Rhythm, 2011, 8(2):278-285.
[12] Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on
the outcome of catheter ablation in patients with paroxysmal
atrial fibrillation and type 2 diabetes mellitus[J]. Europace,
2011, 13(9):1256-1261.
[13] Paglialunga S, Ludzki A, Root-McCaig J, et al. In adipose
tissue, increased mitochondrial emission of reactive oxygen
species is important for short-term high-fat diet-induced
insulin resistance in mice[J]. Diabetologia, 2015, 58(5):1071-
1080.
[14] Fazakerley DJ, Chaudhuri R, Yang P, et al. Mitochondrial CoQ
deficiency is a common driver of mitochondrial oxidants and
insulin resistance[J]. Elife, 2018, 7(7):e32111.
[15] Martelli A, Testai L, Colletti A, et al. Coenzyme Q10: Clinical
applications in cardiovascular diseases[J]. Antioxidants
(Basel), 2020, 9(4):341.
[16] Rivner H, Mitrani RD, Goldberger JJ. Atrial myopathy
underlying atrial fibrillation[J]. Arrhythm Electrophysiol Rev,
2020, 9(2):61-70.
[17] Nattel S. Molecular and cellular mechanisms of atrial fibrosis
in atrial fibrillation[J]. JACC Clin Electrophysiol, 2017,
3(5):425-435.
[18] Chan YH, Chang GJ, Lai YJ, et al. Atrial fibrillation and
its arrhythmogenesis associated with insulin resistance[J].
Cardiovasc Diabetol, 2019,18(1):125.
[19] Sanghai SR, Sardana M, Hansra B, et al. Indexed left atrial
adipose tissue area is associated with severity of atrial
fibrillation and atrial fibrillation recurrence among patients
undergoing catheter ablation[J]. Front Cardiovasc Med, 2018,
199(5):76.
[20] Bohne LJ, Johnson D, Rose RA, et al. The association
between diabetes mellitus and atrial fibrillation: clinical and
mechanistic insights[J]. Front Physiol, 2019, 10(10):135.
[21] Maria Z, Campolo AR, Scherlag BJ, et al. Dysregulation of
insulin-sensitive glucose transporters during insulin resistanceinduced
atrial fibrillation[J]. Biochim Biophys Acta Mol Basis
Dis, 2018, 1864(4):987-996.
[22] Chao TF, Suenari K, Chang SL, et al. Atrial substrate
properties and outcome of catheter ablation in patients
with paroxysmal atrial fibrillation associated with diabetes
mellitus or impaired fasting glucose[J]. Am J Cardiol, 2010,
106(11):1615-1620.
[23] Wang W, Zhang F, Xhen J, et al. P-wave dispersion and
maximum duration are independently associated with insulin
resistance in metabolic syndrome[J]. Ann Endocrinol (Paris),
2014, 75(3):156–161.
[24] Saito I, Hitsumoto S, Maruyama K, et al. Heart rate variability,
insulin resistance, and insulin sensitivity in Japanese adults:
the toon health study[J]. J Epidemiol, 2015,25(9):583-591.
[25] Dilaveris PE, Gialafos EJ, Andrikopoulos GK, et al. Clinical
and electrocardiographic predictors of recurrent atrial
fibrillation[J]. Pacing Clin Electrophysiol, 2000, 23(3):352–
358.
[26] Evangelista I, Nuti R, Picchioni T, et al. Molecular dysfunction
and phenotypic derangement in diabetic cardiomyopathy[J].
Int J Mol Sci, 2019, 20(13):3264.
[27] Tadic M, Ivanovic B, Cuspidi C. What do we currently know
about metabolic syndrome and atrial fibrillation?[J]. Clin
Cardiol, 2013, 36(11):654–662.
[28] Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade
of the renin-angiotensin system reduces the incidence of newonset
diabetes[J]. J Hypertens, 2005, 23(3):463-473.
[29] Marott SC, Nielsen SF, Benn M, et al. Antihypertensive
treatment and risk of atrial fibrillation: a nationwide study[J].
Eur Heart J, 2014, 35(18):1205-1214.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金面上项目（82074346）；黑龙江省博
士后资助经费项目（LBH-Z18253）；黑龙江中医药大学校科研基金
科技创新团队项目（2019TD01）；黑龙江中医药大学校科研基金博
士创新项目（2019BS02）
通信作者：韩宇博，E-mail:hanyb1989@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed69
- 全文下载/Downloads523
- 评论/Comments
